New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For A;R;SPW;SNY;WBMD;CVS;ESV;TER;BSX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | all recent news | >>
November 18, 2014
12:16 EDTSNYSanofi to host seminar on New Medicines
Subscribe for More Information
11:35 EDTBSXBoston Scientific November volatility elevated into investor day
Subscribe for More Information
10:07 EDTRRyder management to meet with Buckingham
Meetings to be held in Kansas City on November 19 and in Texas on November 20 hosted by Buckingham.
07:59 EDTAAgilent downgraded to Market Perform at Cowen
Subscribe for More Information
07:37 EDTBSXStifel to hold a conference
Subscribe for More Information
07:00 EDTAAgilent downgraded to Market Perform from Outperform at Cowen
06:08 EDTBSXBoston Scientific to host investor meeting
Investor meeting to be held on November 19 at 2 pm. Webcast Link
November 17, 2014
16:23 EDTTERGlenview Capital reports 5.53% passive stake in Teradyne
Subscribe for More Information
16:09 EDTAAgilent plans to return $500M in capital to shareholders in FY15
Subscribe for More Information
16:07 EDTAAgilent sees FY15 EPS $1.68-$1.78, consensus $1.74
Subscribe for More Information
16:06 EDTAAgilent sees Q1 EPS 39c-43c, consensus 42c
Subscribe for More Information
16:06 EDTAAgilent reports Q4 EPS 88c, consensus 89c
Subscribe for More Information
15:16 EDTANotable companies reporting after market close
Notable companies reporting after the market close, with earnings consensus, include Agilent Technologies (A), consensus 89c; Jacobs Engineering (JEC), consensus 86c; Urban Outfitters (URBN), consensus 41c; Omega Protein (OME), consensus 30c.
09:08 EDTBSXBoston Scientific announces first U.S. procedures with Symphion completed
Subscribe for More Information
07:16 EDTSNYMilken Institute--Faster Cures to hold a conference
Subscribe for More Information
November 16, 2014
14:44 EDTSNYRegulus, Sanofi present new data enhancing the preclinical profile of RG-012
Subscribe for More Information
12:56 EDTSNYGenzyme’s Lemtrada approved by the FDA
Genzyme, a Sanofi company, announced that the U.S. Food and Drug Administration has approved Lemtrada, alemtuzumab, for the treatment of patients with relapsing forms of multiple sclerosis. Because of its safety profile, the use of Lemtrada should generally be reserved for patients who have had an inadequate response to two or more drugs indicated for the treatment of MS. “Today’s approval is the culmination of more than a decade of work by Genzyme to develop Lemtrada,” said Genzyme President and CEO, David Meeker. “Lemtrada demonstrated superior efficacy over Rebif on annualized relapse rates in the two studies which were the basis for approval. A comprehensive risk evaluation and mitigation strategy will be instituted in order to help detect and manage the serious risks identified with treatment.” The FDA approval of Lemtrada is based on two pivotal randomized Phase III open-label rater-blinded studies comparing treatment with Lemtrada to Rebif in patients with relapsing remitting MS who were either new to treatment or who had relapsed while on prior therapy . In CARE-MS I, Lemtrada was significantly more effective than interferon beta-1a at reducing annualized relapse rates; the difference observed in slowing disability progression did not reach statistical significance. In CARE-MS II, Lemtrada was significantly more effective than interferon beta-1a at reducing annualized relapse rates, and accumulation of disability was significantly slowed in patients given Lemtrada vs. interferon beta-1a. The clinical development program for Lemtrada involved nearly 1,500 patients with more than 6,400 patient-years of safety follow-up. “The unmet need in MS remains high,” said Edward Fox, M.D., Ph.D., Director of the Multiple Sclerosis Clinic of Central Texas. “It is a great day for people living with relapsing forms of MS in the United States, who will now have access to this new meaningful treatment”.
November 14, 2014
14:53 EDTCVS, SNYCVS Express Scripts implementing drug price controls, says Cleveland Research
Cleveland Research believes that CVS (CVS) and Express scripts are implementing rebates and price controls on drug. The firm expects the companies to increase their focus on controlling durg prices next year, and adds that they have already itnroduced prior authorization criteria for hepatitis drug. Publicly traded drug companies include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Makers of hepatits c drugs include AbbVie (ABBV) and Gilead (GILD),
12:53 EDTBSXOmega Advisors gives quarterly update on stakes
NEW STAKES: AerCap Holdings (AER), Nordic American Offshore (NAO), Melco Crown Entertainment (MPEL), Groupon (GRPN), and Ashland (ASH). INCREASED STAKES: QEP Resources (QEP), United Continental (UAL), Cabot Oil & Gas (COG), Actavis (ACT), and KAR Auction Services (KAR). DECREASED STAKES: Sprint (S), SandRidge Energy (SD), Sirius XM Holdings (SIRI), Kinder Morgan (KMI), and Transocean (RIG). LIQUIDATED STAKES: QUALCOMM (QCOM), Ocwen Financial (OCN), Freeport-McMoRan (FCX), Boston Scientific (BSX), and Capital One (COF).
November 13, 2014
17:10 EDTBSXBoston Scientific S-ICD System receives favorable coding, payment designations
Subscribe for More Information
<< 1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use